



Supplementary Figure S1: Change in tumor biomarkers by response (RECIST) during LY3022855 treatment. Tumor biomarkers, CA 15-3, CEA, and PSA, were examined in all patients who received ≥ 1 dose of LY3022855. CA 15-3 (**A**), and CEA (**B**) were examined in MBC patients only, PSA (**C**) was examined in mCRPC patients only. Patients without a valid response assessment ≥ 7 weeks after enrollment that had not already progressed were assigned a best response of Not Evaluable.

Abbreviations: BOR, best overall response; CA 15-3 carcinoma antigen 15-3; CEA, carcinoembryonic antigen; MBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; NE, not evaluable; PSA, Prostate Specific Antigen; PD, progressive disease; SD, stable disease.